Creative Medical Technology Holdings Inc CELZ shares are trading higher Wednesday after the company announced top-line results for its follow-up StemSpine pilot study.
The initial study showed significant efficacy of the StemSpine procedure for treating chronic lower back pain without any serious adverse effects.
In the follow-up study two years later, there were no safety related concerns and the StemSpine procedure resulted in an efficacy rate of 87% in the treated patients.
StemSpine is a patented procedure that utilizes a patient's own bone marrow aspirate for the treatment of chronic lower back pain.
Creative Medical Technology Holdings is a biotechnology holding company focused on regenerative medicine.
See Also: Why Allego Shares Are Surging
CELZ 52-Week Range: $0.01 - $9.00
The stock was up 84.1% at $3.12 at publication time.
Photo: Belova59 from Pixabay.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
